Catamaran Bio gathers $42m

Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing.

Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing. Sofinnova Partners and Lightstone Ventures led the round.

Source: Press Release